Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof inventions 07/09

20090192289 - Omi pdz modulators: The invention provides modulators of Omi PDZ-ligand interaction, and methods of identifying and using these modulators.... Agent: Genentech, Inc.

20090192293 - Antibodies to non-functional p2x7 receptor: The present invention provides antibodies that specifically bind to P2X7 receptors and distinguish between function and non-functional P2X7 receptors, pharmaceutical compositions and kits containing the antibodies, and methods of using the antibodies for the detection, diagnosis and treatment of disease conditions.... Agent: Townsend And Townsend And Crew, LLP

20090192292 - Murine zcytor17 ligand polypeptides and polynucleotides: The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing... Agent: Zymogenetics, Inc. Intellectual Property Department

20090192290 - New bacillus thuringiensis strains and their insecticidal proteins: Four novel Bacillus thuringiensis strains, which are deposited at the BCCM-LMG under accession nos. LMG P-12592, LMG P-12593, LMG P-12594, and LMG P-13493, produce new crystal proteins during sporulation that are toxic to Lepidoptera, more particularly against Noctuidae such as Spodoptera spp. and Agrotis ipsilon, against Pyralidae such as Ostrinta... Agent: Birch Stewart Kolasch & Birch

20090192291 - Production of homotrimeric fusion proteins: The present invention provides method for producing trimeric tumor necrosis factor receptors that are potent inhibitors of their cognate ligands. More particularly, the present invention provides polypeptides that comprise: (1) an extracellular domain of the transmembrane activator and CAML (calcium-signal modulating cyclophilin ligand) interactor (TACI), and (2) a trimerizing polypeptide.... Agent: Zymogenetics, Inc. Intellectual Property Department

20090192294 - Magi polynucleotides, polypeptides, and antibodies: MAGI polypeptides, polynucleotides, antibodies, and methods for producing the same by recombinant techniques are disclosed. Also disclosed are methods for utilizing MAGI polypeptides and polynucleotides in diagnostic assays.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20090192295 - Agents for pre-symptomatic detection and therapeutic targeting of alzheimer's disease and down syndrome in humans: Agents and methods for the diagnosis and therapy of Alzheimer's disease are disclosed. Such agents include three genes located within the region of human chromosome 21 occupied by the APP gene, which are exclusively expressed in Alzheimer's disease, respectively, the proteins encoded and expressed by these genes, the nucleic acid... Agent: Frommer Lawrence & Haug

20090192297 - Carbon membrane having biological molecule immobilized thereon: Disclosed is a biological molecule-immobilized carbon membrane which comprises a porous carbon membrane and a biological molecule (e.g., an enzyme) immobilized on the carbon membrane, wherein the porous carbon membrane has three-dimensional cancellous pores through which fluid can permeate. The carbon membrane can have a large amount of a biological... Agent: Knobbe Martens Olson & Bear LLP

20090192296 - Method for producing denatured substance of lactalbumin: It is intended to provide a method for producing a denatured substance of lactalbumin, particularly the substance showing a cell death inducing activity against a tumor cell, simply at a low cost. The method for producing a denatured substance of lactalbumin includes heating a mixture of domestic animal milk and... Agent: Edwards Angell Palmer & Dodge LLP

20090192299 - Nanolipoprotein particles and related methods and systems for protein capture, solubilization, and/or purification: Provided herein are methods and systems for assembling, solubilizing and/or purifying a membrane associated protein in a nanolipoprotein particle, which comprise a temperature transition cycle performed in presence of a detergent, wherein during the temperature transition cycle the nanolipoprotein components are brought to a temperature above and below the gel... Agent: Llnl/steinfl & Bruno John H. Lee, Assistant Laboratory Counsel

20090192298 - Through-bond energy transfer cassettes, systems and methods: The present disclosure relates, according to some embodiments, to compositions, systems, and methods for preparing and using fluorescent through-bond energy transfer cassettes.... Agent: Baker Botts L.L.P.

20090192300 - Side-chain extended ligation: The invention is directed to methods and compositions for chemical ligation of a first component that includes a carboxythioester and a second component that includes an amino-functionalized compound bearing a branched side chain that includes a removable thiol auxiliary, to give a ligation product having an amide bond at the... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20090187004 - Expression system for enhancing solubility and immunogeneicity of recombinant proteins: Expression system for enhancing solubility and immunogenicity of recombinant proteins. The expression system includes a protein expression vector that contains a chimeric gene encoding a chimeric protein comprising: (a) a first polypeptidyl fragment at the N-terminal end of the chimeric protein, containing a protein transduction domain (PTD), or a fragment... Agent: Ipc Intellectual Property Connections, Inc.

20090187005 - Enhanced purification of antibodies and antibody fragments by apatite chromatography: Methods are disclosed for use of apatite chromatography, particularly without reliance upon phosphate gradients, for purification or separation of at least one intact non-aggregated antibody, or at least one immunoreactive antibody fragment, from an impure preparation. Integration of such methods into multi-step procedures with other fractionation methods are additionally disclosed.... Agent: Pillsbury Winthrop Shaw Pittman LLP

20090187006 - Novel protein, a gene encoding therefor and a method of using the same: An object of the present invention is to search and identify novel antifungal proteins capable of inhibiting the growth of plant pathogenic microorganisms including Magnaporthe grisea and Rhizoctonia solani causing two major rice diseases at relatively low concentrations, and further to clone a gene for said protein. The present invention... Agent: Birch Stewart Kolasch & Birch

20090187007 - Anti-her2 antibody variants: The present invention concerns novel antibody variants, particularly anti-HER2 antibody variants having substitutions at positions within the variable domains of the heavy and light chains... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090187008 - Adsorbent adsorbing antibody against beta 1 adrenoreceptor: The present invention provides a peptide which selectively adsorbs an anti-β1 adrenoreceptor antibody being one of the contributing factors in dilated cardiomyopathy. The peptide of the invention can be immobilized on a carrier in a short period of time with rarely inducing side reactions, and adsorbent for adsorbing an anti-β1... Agent: Connolly Bove Lodge & Hutz LLP

20090187010 - Method of arranging ferritin and method of arranging inorganic particles: To provide a method of arranging ferritin by which a high rate of the number of the molecular film spots on which sole ferritin molecule was arranged in effect, with respect to total number of the molecular film spots provided for arranging ferritin (sole arrangement rate) is achieved is objected... Agent: Mcdermott Will & Emery LLP

20090187009 - Scale-up methods and systems for performing the same: The present invention provides methods of and systems for translating conditions from a small-volume experiment to a larger-volume experiment.... Agent: Townsend And Townsend And Crew, LLP

20090187011 - Method of serum pre-treatment for glycomic analysis: e

20090182119 - Catalytically active peptides: A catalytically active peptide comprising an imidazole function in position i flanked by at least one functional group to be amidated in position i+3+4k, where k is an integer equal to or higher than −1 or in position i−4−4n, wherein n is an integer equal to or higher than 0,... Agent: Buchanan, Ingersoll & Rooney PC

20090182120 - Surface mediated self-assembly of nanoparticles: Materials and methods for surface mediated self assembly of nanoparticles for the isolation of biomolecules is provided.... Agent: Rosenbaum & Associates, P.C.

20090182123 - Method of preparing botulinum neurotoxin type e light chain: The present invention provides a preparation of botulinum toxin light chain type A or E, wherein the preparation is both catalytically active and soluble. Preferably, the preparation consists essentially of amino acid residues 1 through 425 of the botulinum toxin light chain type A. A method of screening inhibitors is... Agent: Quarles & Brady LLP

20090182124 - Novel transcription factor having zinc finger domains: Using an undifferentiated mouse CL6 cell line, DMSO was added to induce its differentiation into cardiac muscular cells in order to obtain gene fragments whose expression elevated upon the induction. The isolated gene had zinc finger domains and showed a significant homology to the Sp1 family genes. Furthermore, a human... Agent: Morrison & Foerster LLP

20090182122 - Nucleic acid sequences encoding transcription factor proteins: Isolated polynucleotides and polypeptides encoded thereby are described, together with the use of those products for making transgenic plants.... Agent: Fish & Richardson P.C.

20090182121 - Regulation of human transmembrane serine protease: Reagents that regulate human transmembrane serine protease activity and reagents that bind to human transmembrane serine protease gene products can be used to regulate extracellular matrix degradation. Such regulation is particularly useful for treating COPD, metastasis of malignant cells, tumor angiogenesis, inflammation, atherosclerosis, neurodegenerative diseases, and pathogenic infections.... Agent: Banner & Witcoff, Ltd.

20090182125 - Porphyrin compound, albumin inclusion compound thereof and artificial oxygen carrier: a

20090182126 - Guanylate-binding protein: A member of the guanylate-binding protein family, designated GBP-4, is provided. Also provided are isolated nucleic acid encoding GBP-4, vectors and host cells containing such nucleic acid molecule, and a method for producing the GBP-4 recombinantly.... Agent: Gates & Cooper LLP Howard Hughes Center

20090182127 - Production of bispecific antibodies: Bispecific antibodies comprising (a) a first light-heavy chain pair having specificity for a first target and a sufficient number of substitutions in its heavy chain constant domain with respect to a corresponding wild-type antibody of the same isotype to significantly reduce the formation of first heavy chain-first heavy chain dimers... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090182128 - Capsular polysaccharide solubilisation and combination vaccines: Precipitated bacterial capsular polysaccharides can be efficiently re-solubilised using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilisation of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The... Agent: Novartis Vaccines And Diagnostics Inc.

20090182129 - Capsular polysaccharide solubilisation and combination vaccines: Precipitated bacterial capsular polysaccharides can be efficiently re-solubilised using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilisation of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The... Agent: Novartis Vaccines And Diagnostics Inc.

20090182130 - Methods of protein production using ovomucoid promoters: Methods of producing protein using a recombinant ovomucoid gene expression controlling region operably linked to one or more useful amino acid coding sequences.... Agent: Synageva Biopharma Corp.

20090182131 - Methods for removing anti-mhc antibodies from a sample: The present invention relates generally to anti-MHC assay methodologies utilizing functionally active, recombinantly produced, and truncated individual soluble MHC trimolecular complexes that are linked to a substrate. The methods include reacting a sample with the substrate having the MHC trimolecular complex linked thereto, whereby antibodies specific for the at least... Agent: Dunlap Codding, P.C.

20090176965 - Sericin having improved antioxidant and tyrosinase inhibitive abilities by irradiation, and methods of making and using the same: Disclosed are sericin having improved antioxidant and tyrosinase inhibitory abilities and increased molecular weight by irradiation, which causes a modification of a sericin molecular structure, a preparation method thereof and use of the irradiated sericin in various applications including food products, cosmetics and/or pharmaceutical products and medicines to improve antioxidant... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090176964 - Stabilized alpha helical peptides and uses thereof: Novel polypeptides and methods of making and using the same are described herein. The polypeptides include cross-linking (“hydrocarbon stapling”) moieties to provide a tether between two amino acid moieties, which constrains the secondary structure of the polypeptide. The polypeptides described herein can be used to treat diseases characterized by excessive... Agent: Fish & Richardson PC

20090176966 - Natural igm antibodies and inhibitors thereof: The invention provides natural IgM antibody inhibitors that may be used to treat various inflammatory diseases or disorders.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20090176967 - Conjugation of fvii: New FVII polypeptides and FVIIa derivatives, uses of such peptides, and methods of producing these polypeptides and derivatives, are provided.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090176968 - Preparation of triazole containing metal chelating agents: New chelating agents as well as their tricarbonyl complexes with technetium and rhenium and the use of these compounds in radiodiagnosis and radiotherapy are described. As a peculiarity of this invention, synthesis and coupling of the chelating systems to (bio)molecules is performed simultaneously. The new chelating agents are coupled to... Agent: Lerner Greenberg Stemer LLP

20090176969 - Cloning genes from streptomyces cyaneogriseus subsp. noncyanogenus for biosynthesis of antibiotics and methods of use: The present invention relates to the complete biosynthetic pathway for the formation of the LL-F28249 compounds and, most importantly, the major component LL-F28249α. The purified and isolated nucleic acid molecule encoding the proteins of the biosynthetic pathway, which is isolated from a wild-type or mutant Streptomyces, is fully described in... Agent: Wyeth Patent Law Group

20090176970 - Preparation of thiosugars and their use: A process for the preparation of a thiosaccharide represented by Saccharide-S-H wherein Saccharide comprises at least 4 sugar units, comprises subjecting a corresponding compound of the formula (P)Saccharide-S-(P) wherein (P) represents an O- or S-protecting group(s), to Birch reduction.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090176971 - Method for determining thermal stability of collagen or collagen-like peptide: The present invention is a method for determining the thermal stability of a collagen peptide, collagen-like peptide or triple-helix construct with the repeating peptide unit Gly-Xaa1-Xaa2. The instant method accounts for the destabilizing effect of peptide repeats which do not conform to the highly stable Gly-Pro-Hyp peptide and for the... Agent: Licata & Tyrrell P.C.

20090171068 - Method of peptide synthesis: A method for solid phase synthesis of Thymosin α1 is devised.... Agent: Nixon & Vanderhye, PC

20090171069 - Peptides and apl-type derivatives of hsp60 and pharmaceutical compositions: Peptides of human heat shock protein of 60 kDa, that constitute epitopes for T cells, as well as their derived peptides, which are modified at the contact sites with the MHC molecule, are useful to induce mechanisms of peripheral tolerance, in particular mechanisms of anergy or mediated by clones of... Agent: Hoffmann & Baron, LLP

20090171070 - Process for the purification of recombinant albumin: A process is provided for the preparation of a highly pure recombinant albumin solution having a nickel ion content of less than 100 ng per gram of albumin. The process comprises subjecting a recombinant albumin to a series of chromatography, concentration, and diafiltration steps.... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090171071 - Pyy agonists and uses thereof: The invention provides PYY3-36 variants and pegylated derivatives thereof and compositions and methods useful in the treatment of conditions modulated by an NPY Y2 receptor agonist.... Agent: Pfizer Inc.

20090171072 - Process for preparing unaggregated antibody fc domains: Methods useful for producing a solution of purified Fc peptide chains are disclosed. The methods employ protein A chromatography to separate high molecular weight, aggregated peptide chains comprising antibody Fc domains from lower molecular weight unaggregated peptide chains that also comprise antibody Fc domains. The solutions of purified Fc peptide... Agent: Philip S. Johnson Johnson & Johnson

20090171073 - Eukaryotic expression system for the incorporation of stable isotopes into proteins: Methods for producing stable isotope-labeled recombinant protein are provided. The methods include isolating a stable isotope-labeled recombinant protein from a Trichoplusia ni larva expressing a recombinant protein, which Trichoplusia ni larva has ingested a food source comprising stable isotope-labeled algae, thereby resulting in incorporation of a stable isotope into the... Agent: Stanford University Office Of Technology Licensing Bozicevic, Field & Francis LLP